Hypercholesterolemia is one of the main risk factors for atherosclerosis and cardiovascular
diseases. The treatment is based on the modification of the diet and lifestyle and if …

Introduction: Evolocumab is a fully human monoclonal immunoglobulin G2 directed against
human proprotein convertase subtilisin/kexin type 9 (PCSK9). It is administered by …

Evolocumab (Repatha®) is a monoclonal antibody targeting proprotein convertase
subtilisin/kexin type 9 (PCSK9) that is administered subcutaneously at a dosage of 140 mg …

The large clinical trials on cardiovascular prevention have demonstrated that the more
atherogenic cholesterol is reduced the greater the preventive benefit, and neither a …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in lipoprotein
metabolism, mainly by modulating LDL receptor activity. Alirocumab is a fully human IgG1 …

Evolocumab (Repatha™) is a fully human monoclonal antibody developed by Amgen that
has been approved as a treatment for hypercholesterolaemia in the EU, and is awaiting …

Lowering of low-density lipoprotein (LDL) cholesterol reduces coronary heart disease
morbidity and mortality, not only in secondary but also in primary prevention. Statins are …

Introduction: Statins are currently the most commonly used agents for treatment of
hypercholesterolemia in patients with atherosclerotic cardiovascular disease. However …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases low-density lipoprotein
cholesterol (LDL-C) concentrations through interference with normal physiologic hepatic …

Introduction: Statins are the mainstay of lipid-lowering therapies targeted at reducing
cardiovascular risk. However, they do not completely obviate risk, not all patients tolerate …